Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02505776
Other study ID # 192024-089
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 8, 2014
Est. completion date May 21, 2018

Study information

Verified date August 2018
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.


Recruitment information / eligibility

Status Completed
Enrollment 1699
Est. completion date May 21, 2018
Est. primary completion date May 21, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

-Patients who have been prescribed GLASH VISTA™ in clinical settings and filled at least one prescription for GLASH VISTA™.

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bimatoprost cutaneous solution 0.03%
Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events Up to 12 Months
Primary Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey Baseline, Month 1
Primary Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey Baseline, Month 4
Primary Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey Baseline, Month 12
See also
  Status Clinical Trial Phase
Completed NCT01229423 - Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects Phase 4
Completed NCT01623479 - An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
Completed NCT01064882 - Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence Phase 2
Completed NCT01023841 - Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Phase 4
Completed NCT01391273 - Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis Phase 3
Completed NCT01391286 - Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis Phase 3

External Links